Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The peptidoglycan pentaglycine cross-bridge is a critical structural component of the Staphylococcus aureus cell wall, distinguishing it from many other bacterial species [5]. It consists of five glycine residues that link the L-lysine of one stem peptide to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of an adjacent stem peptide during peptidoglycan biosynthesis [5]. This cross-linking provides the mechanical strength and rigidity necessary for the bacterium to withstand high internal osmotic pressure [5]. The D-Ala-D-Ala motif within this context is the primary target for glycopeptide antibiotics like vancomycin, which bind to the terminus and sterically hinder the transpeptidation and transglycosylation reactions [1, 4]. Additionally, the pentaglycine bridge itself is the specific target of the endopeptidase lysostaphin, which cleaves the glycine-glycine bonds, leading to rapid bacterial lysis [2]. Because this structure is essential for bacterial survival and absent in eukaryotic cells, it represents a highly effective target for antimicrobial therapy against staphylococcal infections, including methicillin-resistant S. aureus (MRSA) [3, 4].
Glycopeptide antibiotics bind to the D-Ala-D-Ala terminus of the peptidoglycan stem peptide, sterically hindering the transpeptidation and transglycosylation steps of cell wall synthesis [1, 4]. Alternatively, the endopeptidase lysostaphin targets the pentaglycine cross-bridge directly, cleaving the glycine-glycine bonds to cause bacterial cell lysis [2].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidoglycan pentaglycine cross-bridge (Staphylococcus aureus) (Pentaglycine bridge).